Literature DB >> 16607035

Interplay between lipoproteins and bee venom phospholipase A2 in relation to their anti-Plasmodium toxicity.

Carole Guillaume1, Catherine Calzada, Michel Lagarde, Joseph Schrével, Christiane Deregnaucourt.   

Abstract

We previously showed that the in vitro intraerythrocytic development of the malarial agent Plasmodium falciparum is strongly inhibited by secreted phospholipases A(2) (sPLA(2)s) from animal venoms. Inhibition is dependent on enzymatic activity and requires the presence of serum lipoproteins in the parasite culture medium. To evaluate the potential involvement of host lipoproteins and sPLA(2)s in malaria, we investigated the interactions between bee venom phospholipase A(2) (bvPLA(2)), human triglyceride-rich lipoproteins, and infected erythrocytes. Even at high enzyme concentration (100x IC(50)), bvPLA(2) binding to Plasmodium-infected or normal erythrocytes was not detected. On the contrary, tight association with lipoproteins was observed through the formation of buoyant bvPLA(2)/lipoprotein complexes. Direct involvement of the hydrolysis lipid products in toxicity was demonstrated. Arachidonic acid (C20:4), linoleic acid (C18:2), and, to a lesser extent, docosahexaenoic acid (C22:6) appeared as the main actors in toxicity. Minimal oxidation of lipoproteins enhanced toxicity of the lipolyzed particles and induced their interaction with infected or normal erythrocytes. Fresh or oxidized lipolyzed lipoproteins induced the parasite degeneration without host cell membrane disruption, ruling out a possible membranolytic action of fatty acids or peroxidation products in the death process. In conclusion, our data enlighten on the capability of secreted PLA(2)s to exert cytotoxicity via the extracellular generation of toxic lipids, and raise the question of whether such mechanisms could be at play in pathophysiological situations such as malaria.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16607035     DOI: 10.1194/jlr.M600111-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  6 in total

1.  In vitro anti-Plasmodium falciparum properties of the full set of human secreted phospholipases A2.

Authors:  Carole Guillaume; Christine Payré; Ikram Jemel; Louise Jeammet; Sofiane Bezzine; Gajendra S Naika; James Bollinger; Philippe Grellier; Michael H Gelb; Joseph Schrével; Gérard Lambeau; Christiane Deregnaucourt
Journal:  Infect Immun       Date:  2015-03-30       Impact factor: 3.441

2.  Effect of bee venom or proplis on molecular and parasitological aspects of Schistosoma mansoni infected mice.

Authors:  Azza H Mohamed; Sobhy E Hassab El-Nabi; Asmaa E Bayomi; Ahmed A Abdelaal
Journal:  J Parasit Dis       Date:  2014-08-31

3.  Antimalarial Activity of Human Group IIA Secreted Phospholipase A2 in Relation to Enzymatic Hydrolysis of Oxidized Lipoproteins.

Authors:  Mélanie Dacheux; Véronique Sinou; Christine Payré; Louise Jeammet; Daniel Parzy; Philippe Grellier; Christiane Deregnaucourt; Gérard Lambeau
Journal:  Infect Immun       Date:  2019-10-18       Impact factor: 3.441

4.  Expression of a mutated phospholipase A2 in transgenic Aedes fluviatilis mosquitoes impacts Plasmodium gallinaceum development.

Authors:  F G Rodrigues; M N Santos; T X T de Carvalho; B C Rocha; M A Riehle; P F P Pimenta; E G Abraham; M Jacobs-Lorena; C F Alves de Brito; L A Moreira
Journal:  Insect Mol Biol       Date:  2008-04       Impact factor: 3.585

5.  Venomics of the ectoparasitoid wasp Bracon nigricans.

Authors:  Andrea Becchimanzi; Maddalena Avolio; Hamed Bostan; Chiara Colantuono; Flora Cozzolino; Donato Mancini; Maria Luisa Chiusano; Pietro Pucci; Silvia Caccia; Francesco Pennacchio
Journal:  BMC Genomics       Date:  2020-01-10       Impact factor: 3.969

6.  Lipolytic Activity of a Carboxylesterase from Bumblebee (Bombus ignitus) Venom.

Authors:  Yijie Deng; Bo Yeon Kim; Kyeong Yong Lee; Hyung Joo Yoon; Hu Wan; Jianhong Li; Kwang Sik Lee; Byung Rae Jin
Journal:  Toxins (Basel)       Date:  2021-03-26       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.